Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
IDF Home Front Command extends siren warning times for Hezbollah rockets in North - 2UN rights chief says Israeli policy in West Bank 'resembles apartheid system'
- 3Top Smoothie Flavor: What's Your Mix?
- 4Geminid meteor shower, one of the year's most reliable, peaks this weekend
- 55 Destinations Where Airfare Is Dropping The Most For Spring 2026, Per Dollar Flight Club Analysis
- Norovirus is spreading earlier again this year, wastewater data shows
- Find the Mysteries of Effective Objective Setting: Transforming Dreams into Feasible Targets
- Triumph's 400 Range Has Just Changed In India, And Here's Why
- Instructions to Amplify Certifiable Experience While Chasing after an Internet Advertising Degree
- Artemis 2 astronauts are about to see one of the rarest skywatching sights of all — a solar eclipse from beyond the moon
- St George Mining hits record 178m high-grade intercept at Araxá, reinforcing global scale
- Honda’s Biggest Flex Isn’t Its Superbikes, It’s Selling 500K Bikes In One Month
- Cuba says 33 have died of mosquito-borne illnesses as epidemic rages
- Step by step instructions to Safeguard Your Teeth During Sports Exercises
